Biotech and Pharmaceuticals
GSK posts blowout RSV vaccine sales, raises outlook as shots give big pharma a boost
Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. Dado Ruvic | Reuters GlaxoSmithKline on Wednesday lifted its long-term outlook following the smash-hit launch of its new RSV vaccine. The shot targeting the severe and in some cases life-threatening virus booked around £1.2 billion, or $1.5 billion, in […]
Read More
Novo Nordisk beats earnings expectations as Wegovy, Ozempic demand soars
Liselotte Sabroe | Afp | Getty Pictures Novo Nordisk, Europe’s premier firm by market capitalization, on Wednesday noted improved-than-expected 2023 earnings, as sales of its wildly common anti-weight problems and diabetic issues prescription drugs ongoing to soar. The maker of excess weight decline drug Wegovy and diabetic issues drug Ozempic reported an enhance in gross […]
Read More
Vertex non-opioid painkiller shows positive results in critical late-stage trial on acute pain
A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston on Oct. 23, 2019. Brian Snyder | Reuters Vertex Pharmaceuticals on Tuesday said its experimental painkiller, which is being tested as an alternative to addictive opioids, significantly decreased post-surgery pain in late-stage trials The drug, known as VX-548, did not work […]
Read More
Healthy Returns: J&J, Merck and Bristol Myers Squibb are in the hot seat
Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com. Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks […]
Read More
Pfizer beats earnings estimates as declining Covid business performs better than expected
Pfizer CEO Albert Bourla talks during a press conference with European Commission President Ursula von der Leyen after a visit to oversee the production of the Pfizer-BioNtech COVID-19 vaccine at the factory of U.S. pharmaceutical company Pfizer in Puurs, Belgium April 23, 2021. John Thys | Reuters Pfizer on Tuesday posted a surprise adjusted fourth-quarter […]
Read More
Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
The New York Stock Exchange welcomes Johnson & Johnson (NYSE: JNJ) to the podium. NYSE Big pharmaceutical companies such as Bristol Myers Squibb, Merck and Johnson & Johnson face a looming threat that will put tens of billions of dollars in sales at risk between now and 2030, as blockbuster drugs will tumble off a […]
Read More
Merck, Johnson & Johnson CEOs agree to testify in Senate hearing on high drug prices
US Senator Bernie Sanders, Independent of Vermont, speaks during a rally by the People’s Action, protesting pharmaceutical companies’ lobbying against allowing Medicare to negotiate lower prescription drug prices, outside Pharmaceutical Research and Manufacturers of America (PhRMA) headquarters in Washington, DC, September 21, 2021. Saul Loeb | AFP | Getty Images The CEOs of Merck and […]
Read More
Humana stock plunges on dismal 2024 forecast, as insurers face soaring medical costs
Signage is displayed on a Humana Inc. office building in Louisville, Kentucky, U.S., on Sunday, Feb. 3, 2019. Humana is scheduled to release earnings figures on February 6. Photographer: Luke Sharrett/Bloomberg via Getty Images Bloomberg | Bloomberg | Getty Images Shares of Humana plummeted on Thursday after the health insurer issued dismal full-year earnings guidance, […]
Read More
Analysts love these biotech stocks, giving 4 more than 100% upside
The health-care sector may have done poorly in the last couple of years, but analysts are bullish on it right now . “Just two weeks into 2024, the healthcare sector has shrugged off the title of being a notable laggard in 2023,” Citi said in a recent note. Higher interest rates were a key headwind, […]
Read More
Eli Lilly's Zepbound is off to a strong start, but here's what needs to happen to push shares higher
Hopes are sky-high for Eli Lilly’s recently launched weight loss drug Zepbound. Investors will be tuning into the company’s fourth quarter earnings call on Feb. 6, eager to hear more about how that rollout is going. One key statistic will be the number of commercial health insurers providing coverage of the drug, which was approved […]
Read More